Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 370

1.

Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer.

Recondo G, Mezquita L, Facchinetti F, Planchard D, Gazzah A, Bigot L, Rizvi AZ, Frias RL, Thiery JP, Scoazec JY, Sourisseau T, Howarth K, Deas O, Samofalova D, Galissant J, Tesson P, Braye F, Naltet C, Lavaud P, Mahjoubi L, Abou Lovergne A, Vassal G, Bahleda R, Hollebecque A, Nicotra C, Ngo-Camus M, Michiels S, Lacroix L, Richon C, Auger N, De Baere T, Tselikas L, Solary E, Angevin E, Eggermont AM, Andre F, Massard C, Olaussen KA, Soria JC, Besse B, Friboulet L.

Clin Cancer Res. 2019 Oct 4. pii: clincanres.1104.2019. doi: 10.1158/1078-0432.CCR-19-1104. [Epub ahead of print]

PMID:
31585938
2.

HIV-1 Envelope Overcomes NLRP3-Mediated Inhibition of F-Actin Polymerization for Viral Entry.

Paoletti A, Allouch A, Caillet M, Saïdi H, Subra F, Nardacci R, Wu Q, Muradova Z, Voisin L, Raza SQ, Law F, Thoreau M, Dakhli H, Delelis O, Poirier-Beaudouin B, Dereuddre-Bosquet N, Le Grand R, Lambotte O, Saez-Cirion A, Pancino G, Ojcius DM, Solary E, Deutsch E, Piacentini M, Gougeon ML, Kroemer G, Perfettini JL.

Cell Rep. 2019 Sep 24;28(13):3381-3394.e7. doi: 10.1016/j.celrep.2019.02.095.

3.

Disappearance of slan-positive non-classical monocytes for diagnosis of chronic myelomonocytic leukemia with associated inflammatory state.

Tarfi S, Badaoui B, Freynet N, Morabito M, Lafosse J, Toma A, Etienne G, Micol JB, Sloma I, Fenaux P, Solary E, Selimoglu-Buet D, Wagner-Ballon O; Groupe Francophone des Myelodysplasies (GFM).

Haematologica. 2019 Aug 14. pii: haematol.2019.219782. doi: 10.3324/haematol.2019.219782. [Epub ahead of print]

4.

Multilayer intraclonal heterogeneity in chronic myelomonocytic leukemia.

Beke A, Laplane L, Riviere J, Yang Q, Torres-Martin M, Dayris T, Rameau P, Saada V, Bilhou-Nabera C, Hurtado A, Lordier L, Vainchenker W, Figueroa ME, Droin N, Solary E.

Haematologica. 2019 May 2. pii: haematol.2018.208488. doi: 10.3324/haematol.2018.208488. [Epub ahead of print]

5.

Using healthcare claims data to analyze the prevalence of BCR-ABL-positive chronic myeloid leukemia in France: A nationwide population-based study.

Foulon S, Cony-Makhoul P, Guerci-Bresler A, Delord M, Solary E, Monnereau A, Bonastre J, Tubert-Bitter P.

Cancer Med. 2019 Jun;8(6):3296-3304. doi: 10.1002/cam4.2200. Epub 2019 Apr 30.

6.

Dynamic gene regulation by nuclear colony-stimulating factor 1 receptor in human monocytes and macrophages.

Bencheikh L, Diop MK, Rivière J, Imanci A, Pierron G, Souquere S, Naimo A, Morabito M, Dussiot M, De Leeuw F, Lobry C, Solary E, Droin N.

Nat Commun. 2019 Apr 26;10(1):1935. doi: 10.1038/s41467-019-09970-9.

7.

Familial predisposition to TP53/complex karyotype MDS and leukemia in DNA repair-deficient xeroderma pigmentosum.

Sarasin A, Quentin S, Droin N, Sahbatou M, Saada V, Auger N, Boursin Y, Dessen P, Raimbault A, Asnafi V, Schmutz JL, Taïeb A, Menck CFM, Rosselli F, La Rochelle LD, Robert C, Sicre de Fontbrune F, Sébert M, Leblanc T, Kannouche P, De Botton S, Solary E, Soulier J.

Blood. 2019 Jun 20;133(25):2718-2724. doi: 10.1182/blood-2019-01-895698. Epub 2019 Mar 26. No abstract available.

8.

Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia.

Lucas N, Duchmann M, Rameau P, Noël F, Michea P, Saada V, Kosmider O, Pierron G, Fernandez-Zapico ME, Howard MT, King RL, Niyongere S, Diop MK, Fenaux P, Itzykson R, Willekens C, Ribrag V, Fontenay M, Padron E, Soumelis V, Droin N, Patnaik MM, Solary E.

Leukemia. 2019 Oct;33(10):2466-2480. doi: 10.1038/s41375-019-0447-3. Epub 2019 Mar 20.

PMID:
30894665
9.

Towards a classification of stem cells.

Laplane L, Solary E.

Elife. 2019 Mar 13;8. pii: e46563. doi: 10.7554/eLife.46563.

10.

Serpin B1 defect and increased apoptosis of neutrophils in Cohen syndrome neutropenia.

Duplomb L, Rivière J, Jego G, Da Costa R, Hammann A, Racine J, Schmitt A, Droin N, Capron C, Gougerot-Pocidalo MA, Dubrez L, Aral B, Lafon A, Edery P, Ghoumid J, Blair E, El Chehadeh-Djebbar S, Carmignac V, Thevenon J, Guy J, Girodon F, Bastie JN, Delva L, Faivre L, Thauvin-Robinet C, Solary E.

J Mol Med (Berl). 2019 May;97(5):633-645. doi: 10.1007/s00109-019-01754-4. Epub 2019 Mar 7.

PMID:
30843084
11.

A miR-150/TET3 pathway regulates the generation of mouse and human non-classical monocyte subset.

Selimoglu-Buet D, Rivière J, Ghamlouch H, Bencheikh L, Lacout C, Morabito M, Diop M, Meurice G, Breckler M, Chauveau A, Debord C, Debeurme F, Itzykson R, Chapuis N, Willekens C, Wagner-Ballon O, Bernard OA, Droin N, Solary E.

Nat Commun. 2018 Dec 21;9(1):5455. doi: 10.1038/s41467-018-07801-x.

12.

Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosis.

Tarfi S, Harrivel V, Dumezy F, Guy J, Roussel M, Mimoun A, Fenaux P, Chapuis N, Solary E, Selimoglu-Buet D, Wagner-Ballon O; Groupe Francophone des Myélodysplasies (GFM).

Blood Cancer J. 2018 Nov 14;8(11):114. doi: 10.1038/s41408-018-0146-8.

13.

Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): What are the real risks?

Prud'homme C, Deschamps F, Allorant A, Massard C, Hollebecque A, Yevich S, Ngo-Camus M, Gravel G, Nicotra C, Michiels S, Scoazec JY, Lacroix L, Solary E, Soria JC, De Baere T, Tselikas L.

Eur J Cancer. 2018 Nov;103:108-119. doi: 10.1016/j.ejca.2018.08.003. Epub 2018 Sep 14.

PMID:
30223224
14.

Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms.

Patnaik MM, Lasho T, Howard M, Finke C, Ketterling RL, Al-Kali A, Pardanani A, Droin N, Gangat N, Tefferi A, Solary E.

Blood Cancer J. 2018 Aug 22;8(9):82. doi: 10.1038/s41408-018-0120-5. No abstract available.

15.

Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors.

Koeppel F, Bobard A, Lefebvre C, Pedrero M, Deloger M, Boursin Y, Richon C, Chen-Min-Tao R, Robert G, Meurice G, Rouleau E, Michiels S, Massard C, Scoazec JY, Solary E, Soria JC, André F, Lacroix L.

Cancer J. 2018 Jul/Aug;24(4):153-162. doi: 10.1097/PPO.0000000000000322. Review.

PMID:
30119077
16.

Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML.

Niyongere S, Lucas N, Zhou JM, Sansil S, Pomicter AD, Balasis ME, Robinson J, Kroeger J, Zhang Q, Zhao YL, Ball M, Komrokji R, List A, Deininger MW, Fridley BL, Santini V, Solary E, Padron E.

Leukemia. 2019 Jan;33(1):205-216. doi: 10.1038/s41375-018-0203-0. Epub 2018 Jul 19.

PMID:
30026572
17.

Correction: DNA damage and S phase-dependent E2F1 stabilization requires the cIAP1 E3-ubiquitin ligase and is associated with K63-poly-ubiquitination on lysine 161/164 residues.

Glorian V, Allègre J, Berthelet J, Dumetier B, Boutanquoi PM, Droin N, Kayaci C, Cartier J, Gemble S, Marcion G, Gonzalez D, Boidot R, Garrido C, Micheau O, Solary E, Dubrez L.

Cell Death Dis. 2018 Jul 16;9(8):785. doi: 10.1038/s41419-018-0822-4.

18.

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.

Duchmann M, Yalniz FF, Sanna A, Sallman D, Coombs CC, Renneville A, Kosmider O, Braun T, Platzbecker U, Willems L, Adès L, Fontenay M, Rampal R, Padron E, Droin N, Preudhomme C, Santini V, Patnaik MM, Fenaux P, Solary E, Itzykson R.

EBioMedicine. 2018 May;31:174-181. doi: 10.1016/j.ebiom.2018.04.018. Epub 2018 Apr 25.

19.

Does being overweight contribute to longer survival rates in myelodysplastic syndrome?

Solary E, Fontenay M.

Haematologica. 2018 Apr;103(4):559-560. doi: 10.3324/haematol.2018.188854. No abstract available.

20.

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers.

Cabel L, Fuerea A, Lacroix L, Baldini C, Martin P, Hollebecque A, Postel-Vinay S, Varga A, Balheda R, Gazzah A, Michot JM, Marabelle A, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, Scoazec JY, Ammari S, André F, Soria JC, Massard C, Verlingue L.

Oncotarget. 2018 Jan 12;9(11):9741-9750. doi: 10.18632/oncotarget.24188. eCollection 2018 Feb 9.

21.

MUB40 Binds to Lactoferrin and Stands as a Specific Neutrophil Marker.

Anderson MC, Chaze T, Coïc YM, Injarabian L, Jonsson F, Lombion N, Selimoglu-Buet D, Souphron J, Ridley C, Vonaesch P, Baron B, Arena ET, Tinevez JY, Nigro G, Nothelfer K, Solary E, Lapierre V, Lazure T, Matondo M, Thornton D, Sansonetti PJ, Baleux F, Marteyn BS.

Cell Chem Biol. 2018 Apr 19;25(4):483-493.e9. doi: 10.1016/j.chembiol.2018.01.014. Epub 2018 Feb 22.

22.

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

Verlingue L, Hollebecque A, Lacroix L, Postel-Vinay S, Varga A, El Dakdouki Y, Baldini C, Balheda R, Gazzah A, Michot JM, Marabelle A, Mir O, Arnedos M, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, André F, Deutsch E, Scoazec JY, Soria JC, Massard C.

Eur J Cancer. 2018 Mar;92:1-10. doi: 10.1016/j.ejca.2017.12.020. Epub 2018 Feb 3.

PMID:
29413684
23.

Retroperitoneal fibrosis as extramedullary hematopoiesis of a chronic myelomonocytic leukemia.

Ricard L, Abisror N, Droin N, Selimoglu-Buet D, Martin A, Soussan M, Willekens C, Deligny C, Fain O, Solary E, Mekinian A; at the behalf MINHEMON (French network of dysimmune disorders associated to hemopathies).

Leuk Lymphoma. 2018 Oct;59(10):2503-2505. doi: 10.1080/10428194.2018.1427857. Epub 2018 Jan 25. No abstract available.

PMID:
29368535
24.

The severe phenotype of Diamond-Blackfan anemia is modulated by heat shock protein 70.

Gastou M, Rio S, Dussiot M, Karboul N, Moniz H, Leblanc T, Sevin M, Gonin P, Larghéro J, Garrido C, Narla A, Mohandas N, Vainchenker W, Hermine O, Solary E, Da Costa L; French Society of Hematology (SFH); French Society of Immunology and Hematology (SHIP).

Blood Adv. 2017 Oct 10;1(22):1959-1976. doi: 10.1182/bloodadvances.2017008078. eCollection 2017 Oct 10.

25.

Engraftment of chronic myelomonocytic leukemia cells in immunocompromised mice supports disease dependency on cytokines.

Zhang Y, He L, Selimoglu-Buet D, Jego C, Morabito M, Willekens C, Diop MK, Gonin P, Lapierre V, Droin N, Solary E, Louache F.

Blood Adv. 2017 Jun 13;1(14):972-979. doi: 10.1182/bloodadvances.2017004903. eCollection 2017 Jun 13.

26.

Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients.

Koeppel F, Blanchard S, Jovelet C, Genin B, Marcaillou C, Martin E, Rouleau E, Solary E, Soria JC, André F, Lacroix L.

PLoS One. 2017 Nov 21;12(11):e0188174. doi: 10.1371/journal.pone.0188174. eCollection 2017.

27.

Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis.

Sakr R, Renneville A, Saada V, Cotteret S, Martin JE, Droin N, Selimoglu-Buet D, Besse B, Hollebecque A, Marzac C, Pasquier F, Micol JB, De Botton S, Mir O, Solary E, Willekens C.

Leuk Lymphoma. 2018 Jul;59(7):1742-1745. doi: 10.1080/10428194.2017.1397669. Epub 2017 Nov 8. No abstract available.

PMID:
29115897
28.

High sensitivity of the Hematoflow™ solution for chronic myelomonocytic leukemia screening.

Vazquez R, Roussel M, Badaoui B, Freynet N, Tarfi S, Solary E, Selimoglu-Buet D, Wagner-Ballon O; Groupe Francophone des Myélodysplasies (GFM).

Cytometry B Clin Cytom. 2018 Sep;94(5):658-661. doi: 10.1002/cyto.b.21600. Epub 2017 Nov 16.

29.

Resveratrol stimulates the metabolic reprogramming of human CD4+ T cells to enhance effector function.

Craveiro M, Cretenet G, Mongellaz C, Matias MI, Caron O, de Lima MCP, Zimmermann VS, Solary E, Dardalhon V, Dulić V, Taylor N.

Sci Signal. 2017 Oct 17;10(501). pii: eaal3024. doi: 10.1126/scisignal.aal3024.

PMID:
29042482
30.

[The identity of normal and cancer stem cells].

Laplane L, Solary É.

Med Sci (Paris). 2017 Oct;33(10):899-904. doi: 10.1051/medsci/20173310023. Epub 2017 Oct 10. French.

31.

A constitutive BCL2 down-regulation aggravates the phenotype of PKD1-mutant-induced polycystic kidney disease.

Duplomb L, Droin N, Bouchot O, Thauvin-Robinet C, Bruel AL, Thevenon J, Callier P, Meurice G, Pata-Merci N, Loffroy R, Vandroux D, Costa RDA, Carmignac V, Solary E, Faivre L.

Hum Mol Genet. 2017 Dec 1;26(23):4680-4688. doi: 10.1093/hmg/ddx349.

PMID:
28973148
32.

The Microvascular Gap Junction Channel: A Route to Deliver MicroRNAs for Neurological Disease Treatment.

Thuringer D, Solary E, Garrido C.

Front Mol Neurosci. 2017 Aug 4;10:246. doi: 10.3389/fnmol.2017.00246. eCollection 2017.

33.

Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis.

Patnaik MM, Timm MM, Vallapureddy R, Lasho TL, Ketterling RP, Gangat N, Shi M, Tefferi A, Solary E, Reichard KK, Jevremovic D.

Blood Cancer J. 2017 Jul 21;7(7):e584. doi: 10.1038/bcj.2017.66. No abstract available.

34.

Turning the tide in myelodysplastic/myeloproliferative neoplasms.

Deininger MWN, Tyner JW, Solary E.

Nat Rev Cancer. 2017 Jun 23;17(7):425-440. doi: 10.1038/nrc.2017.40. Review.

PMID:
28642604
35.

Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML.

Selimoglu-Buet D, Badaoui B, Benayoun E, Toma A, Fenaux P, Quesnel B, Etienne G, Braun T, Abermil N, Morabito M, Droin N, Solary E, Wagner-Ballon O; Groupe Francophone des Myélodysplasies.

Blood. 2017 Aug 10;130(6):832-835. doi: 10.1182/blood-2017-04-779579. Epub 2017 Jun 13. No abstract available.

PMID:
28611023
36.

Eosinophil-rich tissue infiltrates in chronic myelomonocytic leukemia patients.

Droin N, Lucas N, Parinet V, Selimoglu-Buet D, Humbert M, Saada V, Lambotte O, Solary E, Noël N.

Leuk Lymphoma. 2017 Dec;58(12):2875-2879. doi: 10.1080/10428194.2017.1330468. Epub 2017 Jun 8.

PMID:
28593791
37.

NOX2-dependent ATM kinase activation dictates pro-inflammatory macrophage phenotype and improves effectiveness to radiation therapy.

Wu Q, Allouch A, Paoletti A, Leteur C, Mirjolet C, Martins I, Voisin L, Law F, Dakhli H, Mintet E, Thoreau M, Muradova Z, Gauthier M, Caron O, Milliat F, Ojcius DM, Rosselli F, Solary E, Modjtahedi N, Deutsch E, Perfettini JL.

Cell Death Differ. 2017 Sep;24(9):1632-1644. doi: 10.1038/cdd.2017.91. Epub 2017 Jun 2.

38.

How I treat chronic myelomonocytic leukemia.

Solary E, Itzykson R.

Blood. 2017 Jul 13;130(2):126-136. doi: 10.1182/blood-2017-04-736421. Epub 2017 Jun 1. Review.

PMID:
28572287
39.

DNA damage and S phase-dependent E2F1 stabilization requires the cIAP1 E3-ubiquitin ligase and is associated with K63-poly-ubiquitination on lysine 161/164 residues.

Glorian V, Allègre J, Berthelet J, Dumetier B, Boutanquoi PM, Droin N, Kayaci C, Cartier J, Gemble S, Marcion G, Gonzalez D, Boidot R, Garrido C, Michaud O, Solary E, Dubrez L.

Cell Death Dis. 2017 May 25;8(5):e2816. doi: 10.1038/cddis.2017.222. Erratum in: Cell Death Dis. 2018 Jul 16;9(8):785.

40.

ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia.

Micol JB, Pastore A, Inoue D, Duployez N, Kim E, Lee SC, Durham BH, Chung YR, Cho H, Zhang XJ, Yoshimi A, Krivtsov A, Koche R, Solary E, Sinha A, Preudhomme C, Abdel-Wahab O.

Nat Commun. 2017 May 18;8:15429. doi: 10.1038/ncomms15429.

41.

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.

Duchmann M, Braun T, Micol JB, Platzbecker U, Park S, Pilorge S, Beyne-Rauzy O, Vey N, Sébert M, Gruson B, Dumas PY, Guieze R, Chretien ML, Laribi K, Chait Y, Legros L, Sahnes L, Hirsch P, Salanoubat C, Solary E, Fenaux P, Itzykson R.

Blood Cancer J. 2017 May 12;7(5):e562. doi: 10.1038/bcj.2017.41. No abstract available.

42.

CMML: Clinical and molecular aspects.

Itzykson R, Duchmann M, Lucas N, Solary E.

Int J Hematol. 2017 Jun;105(6):711-719. doi: 10.1007/s12185-017-2243-z. Epub 2017 Apr 28. Review.

PMID:
28455647
43.

Modulation of the inwardly rectifying potassium channel Kir4.1 by the pro-invasive miR-5096 in glioblastoma cells.

Thuringer D, Chanteloup G, Boucher J, Pernet N, Boudesco C, Jego G, Chatelier A, Bois P, Gobbo J, Cronier L, Solary E, Garrido C.

Oncotarget. 2017 Jun 6;8(23):37681-37693. doi: 10.18632/oncotarget.16949.

44.

Serum Gp96 is a chaperone of complement-C3 during graft-versus-host disease.

Seignez A, Joly AL, Chaumonnot K, Hazoumé A, Sanka M, Marcion G, Boudesco C, Hammann A, Seigneuric R, Jégo G, Ducoroy P, Delarue P, Senet P, Castilla-Llorente C, Solary E, Durey MA, Rubio MT, Hermine O, Kohli E, Garrido C.

JCI Insight. 2017 Mar 23;2(6):e90531. doi: 10.1172/jci.insight.90531.

45.

Non-apoptotic functions of caspases in myeloid cell differentiation.

Solier S, Fontenay M, Vainchenker W, Droin N, Solary E.

Cell Death Differ. 2017 Aug;24(8):1337-1347. doi: 10.1038/cdd.2017.19. Epub 2017 Feb 17. Review.

46.

Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease.

Annereau M, Willekens C, El Halabi L, Chahine C, Saada V, Auger N, Danu A, Bermudez E, Lazarovici J, Ghez D, Leary A, Pistilli B, Lemare F, Solary E, de Botton S, Desmaris RP, Micol JB.

Leuk Res. 2017 Apr;55:58-64. doi: 10.1016/j.leukres.2017.01.024. Epub 2017 Jan 20.

PMID:
28131982
47.

CXCR4/CXCL12 axis counteracts hematopoietic stem cell exhaustion through selective protection against oxidative stress.

Zhang Y, Dépond M, He L, Foudi A, Kwarteng EO, Lauret E, Plo I, Desterke C, Dessen P, Fujii N, Opolon P, Herault O, Solary E, Vainchenker W, Joulin V, Louache F, Wittner M.

Sci Rep. 2016 Nov 25;6:37827. doi: 10.1038/srep37827.

48.

Transfer of functional microRNAs between glioblastoma and microvascular endothelial cells through gap junctions.

Thuringer D, Boucher J, Jego G, Pernet N, Cronier L, Hammann A, Solary E, Garrido C.

Oncotarget. 2016 Nov 8;7(45):73925-73934. doi: 10.18632/oncotarget.12136.

49.

Insight on Mutation-Induced Resistance from Molecular Dynamics Simulations of the Native and Mutated CSF-1R and KIT.

Da Silva Figueiredo Celestino Gomes P, Chauvot De Beauchêne I, Panel N, Lopez S, De Sepulveda P, Geraldo Pascutti P, Solary E, Tchertanov L.

PLoS One. 2016 Jul 28;11(7):e0160165. doi: 10.1371/journal.pone.0160165. eCollection 2016.

50.

CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner.

Abdelouahab H, Zhang Y, Wittner M, Oishi S, Fujii N, Besancenot R, Plo I, Ribrag V, Solary E, Vainchenker W, Barosi G, Louache F.

Oncotarget. 2016 Jul 22;8(33):54082-54095. doi: 10.18632/oncotarget.10789. eCollection 2017 Aug 15.

Supplemental Content

Loading ...
Support Center